Astellas’ Mycamine(R) (micafungin) Licensed For Use In Europe To Treat Serious Fungal Infections
May 15th 2008Drug InformationInfectious Diseases / Bacteria / Viruses
The European Medicines Agency (EMEA) has announced the marketing authorisation of MycamineŽ, Astellas Pharma Europe’s treatment for invasive candidiasis, oesophageal candidiasis and prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation. MycamineŽ will initially be available in the U.K and across the European market shortly after this.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
